| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Rheumatology, Departments of Medicine and Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611
Subnanomolar doses of an unaltered, naturally occurring nucleosomal histone peptide epitope, H471–94, when injected s.c. into lupus-prone mice, markedly prolong lifespan by generating CD4+25+ and CD8+ regulatory T cells (Treg) producing TGF-
. The induced Treg cells suppress nuclear autoantigen-specific Th and B cells and block renal inflammation. Splenic dendritic cells (DC) captured the s.c.-injected H471–94 peptide rapidly and expressed a tolerogenic phenotype. The DC of the tolerized animal, especially plasmacytoid DC, produced increased amounts of TGF-, but diminished IL-6 on stimulation via the TLR-9 pathway by nucleosome autoantigen and other ligands; and those plasmacytoid DC blocked lupus autoimmune disease by simultaneously inducing autoantigen-specific Treg and suppressing inflammatory Th17 cells that infiltrated the kidneys of untreated lupus mice. Low-dose tolerance with H471–94 was effective even though the lupus immune system is spontaneously preprimed to react to the autoepitope. Thus, H471–94 peptide tolerance therapy that preferentially targets pathogenic autoimmune cells could spare lupus patients from chronically receiving toxic agents or global immunosuppressants and maintain remission by restoring autoantigen-specific Treg cells.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by grants from the National Institutes of Health (R37-AR39157 and R01-AI41985) and the Solovy Arthritis Research Society (to S.K.D.) and the Arthritis National Research Foundation (to H.-K.K.).
2 Preliminary results on the mechanism of low-dose peptide tolerance were presented as an abstract at the 2005 Annual Meeting of the American College of Rheumatology, Basic Research Conference, San Diego, CA, November 12–17 (H.-K. Kang, M. Liu, and S. K. Datta, 2005. Arthritis Rheum. 52:S32, Abstract BRC4).
3 Address correspondence and reprint requests to Dr. Syamal K. Datta, Division of Rheumatology, Feinberg School of Medicine, Northwestern University, 240 East Huron Street, McGaw No. M300, Chicago, IL 60611. E-mail address: skd257{at}northwestern.edu
4 Abbreviations used in this paper: MHC II, MHC class II; DC, dendritic cell; pDC, plasmacytoid DC; T reg, regulatory T cell; IDO, indoleamine 2,3 dioxygenase; MFI, mean fluorescence intensity.
This article has been cited by other articles:
|
|
 |
|
  L. Zhang, A. M. Bertucci, R. Ramsey-Goldman, R. K. Burt, and S. K. Datta Regulatory T Cell (Treg) Subsets Return in Patients with Refractory Lupus following Stem Cell Transplantation, and TGF-{beta}-Producing CD8+ Treg Cells Are Associated with Immunological Remission of Lupus J. Immunol., November 15, 2009; 183(10): 6346 - 6358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Turner, L. P. Kane, and P. A. Morel Dominant Role of Antigen Dose in CD4+Foxp3+ Regulatory T Cell Induction and Expansion J. Immunol., October 15, 2009; 183(8): 4895 - 4903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Dunne, B. Moran, R. C. Cummins, and K. H. G. Mills CD11c+CD8{alpha}+ Dendritic Cells Promote Protective Immunity to Respiratory Infection with Bordetella pertussis J. Immunol., July 1, 2009; 183(1): 400 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wu, E. Center, G. Tsokos, and H. Weiner Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells Lupus, June 1, 2009; 18(7): 586 - 596. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Mittelbrunn, G. M. del Hoyo, M. Lopez-Bravo, N. B. Martin-Cofreces, A. Scholer, S. Hugues, L. Fetler, S. Amigorena, C. Ardavin, and F. Sanchez-Madrid Imaging of plasmacytoid dendritic cell interactions with T cells Blood, January 1, 2009; 113(1): 75 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Crispin, M. Oukka, G. Bayliss, R. A. Cohen, C. A. Van Beek, I. E. Stillman, V. C. Kyttaris, Y.-T. Juang, and G. C. Tsokos Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys J. Immunol., December 15, 2008; 181(12): 8761 - 8766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zhu, A. L.J. Symonds, J. E. Martin, D. Kioussis, D. C. Wraith, S. Li, and P. Wang Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease J. Exp. Med., September 29, 2008; 205(10): 2295 - 2307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sharabi and E. Mozes The Suppression of Murine Lupus by a Tolerogenic Peptide Involves Foxp3-Expressing CD8 Cells That Are Required for the Optimal Induction and Function of Foxp3-Expressing CD4 Cells J. Immunol., September 1, 2008; 181(5): 3243 - 3251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A La Cava T-regulatory cells in systemic lupus erythematosus Lupus, May 1, 2008; 17(5): 421 - 425. [Abstract] [PDF]
|
|
|
|
|
|
S. Datta and C Mauri Signalling defects and cellular interactions (2) Lupus, March 1, 2008; 17(3): 247 - 250. [PDF]
|
|
|
|
|
|
R. P. Singh, A. La Cava, and B. H. Hahn pConsensus Peptide Induces Tolerogenic CD8+ T Cells in Lupus-Prone (NZB x NZW)F1 Mice by Differentially Regulating Foxp3 and PD1 Molecules J. Immunol., February 15, 2008; 180(4): 2069 - 2080. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
